Results
- Showing results for:
- Reset all filters
Search results
-
Journal articleNewson M, Roseman L, Haslam SA, 2026,
Towards social curative psychedelic treatment.
, Discov Ment Health -
Journal articleAgnorelli C, Peill J, Sawicka G, et al., 2026,
Detecting neuroplastic effects induced by ketamine in healthy human subjects: A multimodal approach.
, J Cereb Blood Flow MetabWe investigated ketamine's neuroplastic effects in healthy human subjects using integrated Positron Emission Tomography (PET)/Magnetic Resonance Imaging (MRI) measures before and 1-8 days after a single psychedelic dose of ketamine (1 mg/kg, intravenous). Eleven male participants underwent two PET/MRI scans with [11C]-UCBJ (synaptic density/plasticity), 1H-MRS (glutamate and GABA) and resting-state fMRI (intrinsic brain activity, functional connectivity), before and after ketamine. While group-level analyses showed no significant increases in PET synaptic markers, ketamine administration resulted in significantly elevated glutamate levels within the anterior cingulate cortex (ACC). Functional connectivity analyses revealed reduced coupling between the ACC and the dorsolateral prefrontal cortex (dlPFC) and increased coupling between the ACC and the amygdala in the days following ketamine administration. Our multimodal analysis revealed that participants showing an increase in [11C]-UCBJ volume distribution (VT), a putative index of synaptic plasticity, showed a correlated reduction in intrinsic activity within regions belonging to the default mode network (DMN). By linking molecular, cellular and network-level changes, our results point to the DMN as a central hub where ketamine may reshape brain hierarchies in the long term, providing new directions for understanding its therapeutic mechanisms and developing targeted treatments.
-
Journal articleAgnorelli C, Garling HD, Paterson LM, et al., 2026,
Recent advances in PET measures of brain 5-HT release.
, J Cereb Blood Flow MetabSerotonin (5-hydroxytryptamine, 5-HT) is a neuromodulator underpinning various psychological and physiological processes, with dysregulation implicated in numerous psychiatric disorders. Non-invasive measurement of endogenous 5-HT release in the living human brain is essential to advance understanding of the serotonergic system. The combination of Positron Emission Tomography (PET) neuroimaging of serotonergic receptors with pharmacological and behavioural challenges that stimulate endogenous 5-HT release, offers a unique approach to quantify 5-HT dynamics in vivo. In 2010, Paterson and colleagues concluded in a thorough review that measures of 5-HT release were constrained by limitations in the sensitivity of available tracers and potency of pharmacological challenges. Novel tracers combined with optimised pharmacological challenge paradigms have demonstrated sensitivity to changes in endogenous 5-HT, enabling reproducible detection of acute 5-HT release in both preclinical and human studies in the last 15 years of research. These include the use of agonist radioligands with preferential binding to high-affinity receptor states, such as [11C]AZ10419369 and [11C]Cimbi-36, antagonist tracers, such as [18F]Altanserin, refined challenge designs using pharmacological 5-HT releasers, such as fenfluramine and amphetamine, and the integration of hybrid PET/MR imaging to assess neurovascular aspects. These advances have shifted the field from questioning feasibility to addressing optimal strategies for measuring serotonergic dynamics.
-
Journal articleFabiano N, Stubbs B, Lawrence DW, et al., 2026,
The combination of exercise and psychedelics for the treatment of major depressive disorder.
, Discov Ment Health, Vol: 6Upwards of 50% of people do not respond to the primary treatment modalities for major depressive disorder (MDD), which has led to increased attention and use of alternative methods, including exercise and psychedelics. While interventions using either exercise or psychedelics have demonstrated largely positive results in isolation, their synergistic potential has yet to be explored. As such, this commentary provides an overview of exercise/psychedelics as a treatment for depression and their potential synergy and/or complementarity. From a biological perspective, psychedelics acutely enhance brain-derived neurotrophic factor (BDNF) signalling, while exercise provides sustained BDNF elevation; psychedelics enhance neuroplasticity largely in the cortex (with only modest effects in the hippocampus), while exercise boosts hippocampal neurogenesis; psychedelics increase glutamate release via stimulation of 5-HT2A receptors on pyramidal neurons, while exercise enhances glutamatergic transmission via the endocannabinoid system and reduction of systemic inflammation; both boost serotonin release; and psychedelics temporarily disrupt functional connectivity between the hippocampus and default mode network (DMN), while exercise normalizes this connectivity, which may sustain post-psychedelic gains. Through the lens of psychological and behaviour change, psychedelics appear to facilitate the adoption or maintenance of physical activity habits, increase psychological flexibility, and since exercise is associated with emotional resilience to acute stress, this may allow users to experience deeper immersion and exploration during their psychedelic experience, improving antidepressant outcomes. In summary, exercise and psychedelics have numerous potential complementary mechanisms, therefore, future research is warranted to explore the efficacy, tolerability, safety, and neurobiology of this combination.
-
Journal articleNutt D, 2026,
Medicines for Anxiety: A Hundred Years of Tranquillity and More to Come?
, Hum Psychopharmacol, Vol: 41 -
Journal articleLipson J, Kettner H, Carhart-Harris R, et al., 2026,
Baseline Mood and "Relational Triad" Predict Acute Qualities of Psychedelic Experience.
, Behav Sci (Basel), Vol: 16, ISSN: 2076-328XBACKGROUND: The quality and valence of psychedelic experiences are influenced by a range of psychological and contextual factors. This study examines baseline mood and the "relational triad"-comprising social connectedness, mindfulness, and spirituality-as potential predictors of the quality of naturalistic psychedelic experiences. METHODS: Data were drawn from the Predicting Responses to Psychedelics dataset, a longitudinal study tracking 654 individuals planning to take a psychedelic substance. Participants completed self-report measures at five time points, before and after ingestion. Baseline mood (depression, anxiety, and wellbeing) and relational triad factors were assessed at Timepoint 1, while acute psychedelic experience quality was measured at Timepoint 3 using validated scales (MEQ-30, CEQ, and ASC). RESULTS: Mystical and challenging experiences were weakly but positively correlated. Baseline depression and anxiety were predictive of more challenging experiences but not of mystical-type experiences, while baseline wellbeing predicted more mystical and less challenging experiences. Mindfulness and spirituality were positively associated with mystical experiences, while social connectedness and mindfulness were inversely associated with challenging experiences. CONCLUSIONS: These findings extend previous research by demonstrating that baseline psychological and relational factors shape the nature of psychedelic experiences.
-
Journal articleKurtin DL, Herlinger K, Hayes A, et al., 2026,
Task-related differences in network connectivity and dynamics in people with severe opioid use disorder compared with healthy controls
, Translational Psychiatry, ISSN: 2158-3188One approach to addressing the immense unmet need for treatments of severe opioid use disorder (sOUD) is to understand more about associated changes in the brain’s reward circuitry. It has been shown that during reward anticipation in the Monetary Incentive Delay (MID) task, people with severe substance use disorder (SUD) show blunted responses in reward neural circuitry compared with healthy controls (HC). Conversely, drug-related cues result in heightened responses in the same neural reward circuitry in those with SUD compared with HC. However, it is unclear how such dysfunctional reward processing is related to neural correlates of other processes commonly dysregulated in addiction, such as attention and cognition. The aim of this work was to evaluate whether people with sOUD show different relationships between reward networks to networks that regulate cognition, attention, sensory processes, and more. Then, we evaluated whether there is a spatial relationship between differences in brain function and atlases of μ-opioid receptor (MOR) and dopamine D2 receptor (DRD2) availability. We collected fMRI data while people with sOUD receiving methadone (MD; n = 25) and HC (n = 22) completed the MID and cue reactivity tasks. We evaluated differences in functional connectivity (FC) and measures of brain state dynamics. Partial least squared (PLS) analysis computed the spatial relationship between FC metrics to MOR and D2DR availability. We found that MD participants generally exhibited weaker miFC compared to HC in both tasks except when comparing the difference in miFC during anticipation of monetary reward or drug related stimuli vs neutral stimuli. Contrasts between rewarding or drug-related to neutral stimuli showed MD participants had stronger miFC between reward/anti-reward networks to regions in the control network and default mode Network (DMN) in both tasks. Analysis of brain state dynamics showed the DMN was more prevalent i
-
Journal articleErritzoe D, Barba T, Benway T, et al., 2026,
A short-acting psychedelic intervention for major depressive disorder: a phase IIa randomized placebo-controlled trial.
, Nat Med, Vol: 32, Pages: 591-598Major depressive disorder (MDD) is a leading cause of disability worldwide, yet many patients have inadequate responses to current treatments. Dimethyltryptamine (DMT), a serotonergic psychedelic with rapid onset and short duration, shows promise as a potential antidepressant (AD), although clinical evidence in MDD remains limited. We conducted a phase IIa, double-blind, placebo-controlled, randomized clinical trial to evaluate the efficacy and safety of intravenous DMT (SPL026; DMT fumarate) in adults with moderate-to-severe MDD. Participants received a single 21.5-mg dose of DMT or placebo infused over 10 min, along with supportive psychotherapeutic support, followed by a 2-week assessment. A subsequent open-label phase offered all participants a second DMT dose. The primary outcome was the change in Montgomery-Åsberg Depression Rating Scale (MADRS) at 2 weeks. Secondary outcomes included response (≥50% reduction in MADRS score) and remission (MADRS ≤ 10). A total of 34 participants were randomized, 17 to placebo-active and 17 to active-active. At 2 weeks, the DMT group showed a significantly greater reduction in MADRS score than placebo (mean difference = -7.35; 95% CI = -13.62 to -1.08; P = 0.023). In the open-label phase, AD effects persisted up to 3 months, with no significant differences between those who received one versus two doses. Adverse events were mostly mild to moderate, commonly infusion site pain, nausea and transient anxiety. No serious adverse events occurred. A single dose of DMT with psychotherapeutic support produced a rapid, significant reduction in depressive symptoms, sustained up to 3 months. The treatment was well-tolerated and safe. ClinicalTrials.gov registration: NCT04673383 .
-
Journal articleSiegel JS, Liston C, Nicol GE, et al., 2026,
The science of psychedelic medicine.
, Nat Med, Vol: 32, Pages: 449-462Classic psychedelics typically act at the serotonin 5-HT2A receptor to profoundly alter brain function and consciousness. Research on these compounds has accelerated. Major strides have been made in understanding their unique mechanisms of action and clinical potential. This Review outlines the state of psychedelic science, spanning cellular mechanisms, systems neuroscience and clinical investigation. We show that preclinical and human research findings converge on two complementary processes: acute neural desynchronization, which destabilizes entrenched network patterns, and subacute neuroplasticity, which opens a window for psychological and behavioral change. We review evidence of therapeutic response across neuropsychiatric indications and consider how this integrates with mechanistic findings. We also explore challenges and opportunities, including discrepancies between preclinical evidence that non-hallucinogenic psychedelic analogs engage putative therapeutic mechanisms, and clinical evidence linking the subjective experience to therapeutic response; the risks inherent to enhanced neuroplasticity; and questions surrounding trial design, scalability and regulatory approval. The growth of psychedelic science and medicine may compel a fundamental rethinking of the relationship between subjective experience and biological change in psychiatry.
-
Journal articleZafar R, 2026,
High hopes? Precision psychedelic addiction medicine
, Frontiers in Psychiatry, ISSN: 1664-0640Despite decades of neuroscience research and significant investment in addiction neuroimaging, clinical outcomes for individuals with substance use and behavioural addictions remain poor. Only 1.8% of people with substance use disorders receive effective treatment, highlighting a major disconnect between mechanistic understanding and clinical utility. This paper calls for a reorientation of addiction neuroscience, from a predominantly diagnostic focus toward a theragnostic framework, in which biomarkers are used to stratify patients, guide treatment decisions, and predict outcomes. We argue that the integration of translational neuroimaging biomarkers, particularly fMRI, EEG, and PET, within psychedelic addiction research offers a unique and timely opportunity to catalyse this shift. Psychedelic compounds such as psilocybin represent a new class of therapeutics capable of engaging neuroplasticity, reward and emotional processing, and cognitive control networks central to addiction pathophysiology. We review how acute and pre– post neuroimaging paradigms can index pharmacodynamic effects and longer-term treatment response and propose a roadmap for embedding biomarkers in early and late phase clinical trials. Drawing on ongoing studies at the Centre for Psychedelic Research at Imperial College London, we outline how multimodal biomarkers are being co-developed alongside clinical trials in gambling and opioid use disorders to identify biotype-specific responses and build a deeply phenotyped treatment population. We argue that these biomarkers, if validated, could serve as regulatory-grade tools for drug theragnostic co-development, mirroring successful models in oncology and 2 neurology. Importantly, we emphasise that realising this vision will require robust multi-stakeholder collaboration, including academia, industry, regulatory agencies, funders, healthcare systems, and patient groups alongside dedicated investment to build a scalable theragnostic infrastruct
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.
